Cancer Chemother Pharmacol. 2021 Nov;88(5):837-844. doi: 10.1007/s00280-021-04327-w. Epub 2021 Jul 31.

Influence of FPGS, ABCC4, SLC29A1, and MTHFR genes on the pharmacogenomics of fluoropyrimidines in patients with gastrointestinal cancer from the Brazilian Amazon.

Cancer chemotherapy and pharmacology

Marianne Rodrigues Fernandes, Juliana Carla Gomes Rodrigues, Elizabeth Ayres Fragoso Dobbin, Lucas Favacho Pastana, Danielle Feio da Costa, Williams Fernandes Barra, Antônio André Conde Modesto, Paula Baraúna de Assumpção, Artur Luiz da Costa Silva, Sidney Emanuel Batista Dos Santos, Rommel Mario Rodriguez Burbano, Paulo Pimentel de Assumpção, Ney Pereira Carneiro Dos Santos

PMID: 34331561 DOI: 10.1007/s00280-021-04327-w

Abstract

PURPOSE: Fluoropyrimidines are one of the most used drug class to treat cancer patients, although they show high levels of associated toxicity. This study analyzed 33 polymorphisms in 17 pharmacogenes involved with the pharmacogenomics of fluoropyrimidines, in gastrointestinal cancer patients undergoing fluoropyrimidine-based treatment in the Brazilian Amazon.

METHODS: The study population was composed of 216 patients, 92 of whom have an anatomopathological diagnosis of gastric cancer and 124 of colorectal cancer. The single nucleotide polymorphisms (SNP) were genotyped by allelic discrimination using the TaqMan OpenArray Genotyping technology, with a panel of 32 customized assays, run in a QuantStudio ™ 12K Flex Real-Time PCR System (Applied Biosystems, Life Technologies, Carlsbad USA). Ancestry analysis was performed using 61 autosomal ancestry informative markers (AIMs).

RESULTS: The study population show mean values of 48.1% European, 31.1% Amerindian, and 20.8% African ancestries. A significant risk association for general and severe toxicity was found in the rs4451422 of FPGS (p = 0.001; OR 3.40; CI 95% 1.65-7.00 and p = 0.006; OR 4.63; CI 95% 1.56-13.72, respectively) and the rs9524885 of ABCC4 (p = 0.023; OR 2.74; CI 95% 1.14-6.65 and p = 0.024; OR 5.36; IC 95% 1.24-23.11, respectively) genes. The rs760370 in the SLC29A1 gene (p = 0.009; OR 6.71; CI 95% 1.16-8.21) and the rs1801133 in the MTHFR toxicity (p = 0.023; OR 3.09; CI 95% 1.16-8.21) gene also demonstrated to be significant, although only for severe toxicity. The results found in this study did not have statistics analysis correction.

CONCLUSION: Four polymorphisms of the ABCC4, FPGS, SLC29A1, and MTHFR genes are likely to be potential predictive biomarkers for precision medicine in fluoropyrimidine-based treatments in the population of the Brazilian Amazon, which is constituted by a unique genetic background.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Keywords: ABCC4; FPGS; Fluoropyrimidine; MTHFR; Pharmacogenomics; SLC29A1

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424 - PubMed
2. Campbell JM, Bateman E, Peters MDJ, Bowen JM, Keefe DM, Stephenson MD (2016) Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses. Pharmacogenomics 17:435–451 - PubMed
3. Fellner C (2017) Promising drugs in clinical development to treat advanced colorectal cancer. Pharm Ther 42:262–265 - PubMed
4. Matsusaka S, Lenz HJ (2015) Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin Drug Metab Toxicol 11:811–821 - PubMed
5. Meulendijks D, Cats A, Beijnen JH, Schellens JHM (2016) Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity—ready for clinical practice? Cancer Treat Rev 50:23–34 - PubMed
6. Gbeto CC, Quaranta S, Mari R, Fanciullino R, Roche C, Nahon S et al (2019) Lethal toxicities after capecitabine intake in a previously 5-FU-treated patient: why dose matters with dihydropryimidine dehydrogenase deficiency. Pharmacogenomics 20:931–938 - PubMed
7. Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E et al (2019) A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer 107:60–67 - PubMed
8. Wigle TJ, Tsvetkova EV, Welch SA, Kim RB (2019) DPYD and fluorouracil-based chemotherapy: mini review and case report. Pharmaceutics. https://doi.org/10.3390/pharmaceutics11050199 - PubMed
9. Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF et al (2012) Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 92:414–417 - PubMed
10. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ et al (2018) Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103:210–216 - PubMed
11. Santos NPC, Ribeiro-Rodrigues EM, Ribeiro-dos-Santos ÂKC, Pereira R, Gusmão L, Amorim A et al (2010) Assessing individual interethnic admixture and population substructure using a 48-insertion-deletion (INSEL) ancestry-informative marker (AIM) panel. Hum Mutat 31:184–190 - PubMed
12. de Ramos BRA, D’Elia MPB, Amador MAT, Santos NPC, Santos SEB, da Cruz CE et al (2016) Neither self-reported ethnicity nor declared family origin are reliable indicators of genomic ancestry. Genetica 144:259–265 - PubMed
13. Rodrigues-Soares F, Suarez-Kurtz G (2019) Pharmacogenomics research and clinical implementation in Brazil. Basic Clin Pharmacol Toxicol 124:538–549 - PubMed
14. Roden DM, McLeod HL, Relling MV, Williams MS, Mensah GA, Peterson JF et al (2019) Pharmacogenomics. Lancet 394:521–532 - PubMed
15. The National Center for Biotechnology Information (2020) PubMed/Medline-NCBI. https://www.ncbi.nlm.nih.gov/pubmed/ - PubMed
16. The National Center for Biotechnology Information (2020) dbSNP—short genetic variations. https://www.ncbi.nlm.nih.gov/SNP/ - PubMed
17. The Pharmacogenomics Knowledgebase (2020) PharmGK. https://www.pharmgkb.org/ - PubMed
18. Ramos BR de A, Mendes ND, Tanikawa AA, Amador MAT, Santos NPC dos, Santos SEB dos et al (2016) Ancestry informative markers and selected single nucleotide polymorphisms in immunoregulatory genes on preterm labor and preterm premature rupture of membranes: a case control study. BMC Pregnancy Childbirth. https://doi.org/10.1186/s12884-016-0823-1 - PubMed
19. González JR, Armengol L, Solé X, Guinó E, Mercader JM, Estivill X et al (2007) SNPassoc: an R package to perform whole genome association studies. Bioinformatics 23:644–645 - PubMed
20. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U et al (2015) Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16:1639–1650 - PubMed
21. Lunenburg CATC, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JHM et al (2016) Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: ready for prime time. Eur J Cancer 54:40–48 - PubMed
22. Suarez-Kurtz G, Parra EJ (2018) Population diversity in pharmacogenetics: a Latin American Perspective, 1st edn. Elsevier Inc. https://doi.org/10.1016/bs.apha.2018.02.001 - PubMed
23. Food and Drug Administration. Table of Pharmacogenomics Biomarkers in Drug Labeling. - PubMed
24. Wright NJ, Lee SY (2019) Structures of human ENT1 in complex with adenosine reuptake inhibitors. Nat Struct Mol Biol 26:599–606 - PubMed
25. Thorn CF, Marsh S, Carrillo MW, McLeod HL, Klein TE, Altman RB (2011) Pharm GKB summary: Fluoropyrimidine pathways. Pharmacogenet Genom 21:237–242 - PubMed
26. Tsujie M, Nakamori S, Nakahira S, Takeda S, Takahashi Y, Hayashi N et al (2006) Schedule-dependent therapeutic effects of gemcitabine combined with uracil-tegafur in a human pancreatic cancer xenograft model. Pancreas 33:142–147 - PubMed
27. Saif MW, Lee Y, Kim R (2012) Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer. Ther Adv Med Oncol 4:341–346 - PubMed
28. Lamba JK (2009) Genetic factors influencing cytarabine therapy. Pharmacogenomics 10:1657–1674 - PubMed
29. Kim JH, Lee C, Cheong HS, Koh Y, Ahn KS, Kim HL et al (2016) SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia. Cancer Chemother Pharmacol 78:533–540 - PubMed
30. Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Dadduzio V et al (2017) Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer 86:197–206 - PubMed
31. Mei R, Chi X, Wu R, Xu H, Wang X, Gao X et al (2016) Sustained viral response and treatment-induced cytopenia correlate with SLCs and KLF12 genotypes in interferon/ribavirin-treated Chinese chronic hepatitis C patients. J Gastroenterol Hepatol 31:1489–1497 - PubMed
32. Allegra S, Cusato J, De Nicolò A, Boglione L, Gatto A, Cariti G et al (2015) Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomed Pharmacother 69:47–55 - PubMed
33. Cancer Institute N (2017) Common Terminology Criteria for Adverse Events (CTCAE) Common Terminology Criteria for Adverse Events (CTCAE) v5.0. https://www.meddra.org/ . Accessed 7 Sep 2020 - PubMed
34. Berthier J, Arnion H, Saint-Marcoux F, Picard N (2019) Multidrug resistance-associated protein 4 in pharmacology: Overview of its contribution to pharmacokinetics, pharmacodynamics and pharmacogenetics. Life Sci. https://doi.org/10.1016/j.lfs.2019.06.015 - PubMed
35. Pellicer M, García-González X, García MI, Blanco C, García-Alfonso P, Robles L et al (2017) Use of exome sequencing to determine the full profile of genetic variants in the fluoropyrimidine pathway in colorectal cancer patients affected by severe toxicity. Pharmacogenomics 18:1215–1223 - PubMed
36. Islam MS, Islam MS, Parvin S, Ahmed MU, Sayeed MSB, Uddin MMN et al (2015) Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients. Tumor Biol 36:5451–5457 - PubMed
37. Sloan JA, De Andrade M, Decker P, Wampfler J, Oswold C, Clark M et al (2012) Genetic variations and patient-reported quality of life among patients with lung cancer. J Clin Oncol 30:1699–1704 - PubMed
38. Sakamoto E, Tsukioka S, Oie S, Kobunai T, Tsujimoto H, Sakamoto K et al (2008) Folylpolyglutamate synthase and γ-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. Biochem Biophys Res Commun 365:801–807 - PubMed
39. Tsukioka S, Sakamoto E, Tsujimoto H, Nakagawa F, Saito H, Uchida J et al (2011) In vivo evidence for a significant role of folylpolyglutamate synthase in combined chemotherapy with oral fluoropyrimidine, UFT or S-1, and leucovorin. Oncol Rep 25:1407–1412 - PubMed
40. Sohn KJ, Smirnakis F, Moskovitz DN, Novakovic P, Yates Z, Lucock M et al (2004) Effect of folylpolyglutamate synthetase modulation on chemosensitivity of colon cancer cells to 5-fluorouracil and methotrexate. Gut 53:1825–1831 - PubMed
41. Yanagimachi M, Naruto T, Hara T, Kikuchi M, Hara R, Miyamae T et al (2011) Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br J Clin Pharmacol 71:237–243 - PubMed
42. Sala-Icardo L, Lamana A, Ortiz AM, García Lorenzo E, Moreno Fresneda P, García-Vicuña R et al (2017) Impact of genetic variants of ATP binding cassette B1, AICAR transformylase/IMP cyclohydrolase, folyl-polyglutamatesynthetase, and methylenetetrahydrofolatereductase on methotrexate toxicity. Reumatol Clin 13:318–325 - PubMed
43. Shimamoto Y, Nukatsuka M, Takechi T, Fukushima M (2016) Association between mRNA expression of chemotherapy-related genes and clinicopathological features in colorectal cancer: a large-scale population analysis. Int J Mol Med 37:319–328 - PubMed
44. Maezawa Y, Sakamaki K, Oue N, Kimura Y, Hashimoto I, Hara K et al (2020) High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. J Cancer Res Clin Oncol 146:75–86 - PubMed
45. Levin BL, Varga E (2016) MTHFR: addressing genetic counseling dilemmas using evidence-based literature. J Genet Couns 25:901–911 - PubMed
46. Moll S, Varga EA (2015) Homocysteine and MTHFR mutations. Circulation 132:e6–e69 - PubMed
47. Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I, Basbinar Y (2018) DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med. https://doi.org/10.3390/jpm8040045 - PubMed
48. Cecchin E, Perrone G, Nobili S, Polesel J, De Mattia E, Zanusso C et al (2015) MTHFR-1298 A>C (rs1801131) is a predictor of survival in two cohorts of stage II/III colorectal cancer patients treated with adjuvant fluoropyrimidine chemotherapy with or without oxaliplatin. Pharmacogenomics J 15:219–225 - PubMed
49. Afzal S, Jensen SA, Vainer B, Vogel U, Matsen JP, Sørensen JB et al (2009) MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol 20:1660–1666 - PubMed
50. Jennings BA, Kwok CS, Willis G, Matthews V, Wawruch P, Loke YK (2012) Functional polymorphisms of folate metabolism and response to chemotherapy for colorectal cancer, a systematic review and meta-analysis. Pharmacogenet Genom 22:290–304 - PubMed
51. Zhong L, He X, Zhang Y, Chuan JL, Chen M, Zhu SM et al (2018) Relevance of methylenetetrahydrofolate reductase gene variants C677T and A1298C with response to fluoropyrimidinebased chemotherapy in colorectal cancer: a systematic review and meta-analysis. Oncotarget 9:31291–31301 - PubMed

Publication Types

• Journal Article
• Research Support, Non-U.S. Gov't